References
- Brown, A. M. : Drugs, hERG and sudden death. Cell Calcium 35, 543 (2004) https://doi.org/10.1016/j.ceca.2004.01.008
- Topol, E. J. : Failing the public health - Rofecoxib, Merck, and the FDA. New Eng. J. Med. 351, 1707 (2004) https://doi.org/10.1056/NEJMp048286
- Fermini, B. and Fossa, A. A. : The impact of drug-induced QT interval prolongation on drug discovery and development. Nature Rev. 2, 439 (2003) https://doi.org/10.1038/nrd1108
- Redfern, W. S., et al. : Relationship between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32 (2003) https://doi.org/10.1016/S0008-6363(02)00846-5
- ICH Harmonized Tripartite Guideline (S7B revised). The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals, step 3 (2004)
- ICH Harmonized Tripartite Guideline (E14). The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs, step 3 (2004)
- Guth, B. D., et al. : Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization. J. Pharmacol. Toxicol. Methods 49, 159 (2004) https://doi.org/10.1016/j.vascn.2004.02.006
- Antzelevitch, C. and Shimizu, W. : Cellular mechanisms underlying the long QT syndrome. Curr. Opin. Cardiol. 17, 43 (2002) https://doi.org/10.1097/00001573-200201000-00007
- Finlayson, K., et al. : Acquired QT interval prolongation and hERG : implications for drug discovery and development. Eur. J. Pharmacol. 500, 129 (2004) https://doi.org/10.1016/j.ejphar.2004.07.019
- ICH Harmonized Tripartite Guideline (S7A). Safety pharmacology studies for human pharmaceuticals (2001)
- Abhash, C., et al. : QT interval prolongation in diphenhydramine toxicity. International Journal of Cardiology 98, 341 (2005) https://doi.org/10.1016/j.ijcard.2003.10.051
- Sype, J. W., et al. : Prolonged QT interval with markedly abnormal ventricular repolarization in diphenhydramine overdose. International Journal of Cardiology 99(2), 333 (2005) https://doi.org/10.1016/j.ijcard.2003.11.035
- Truett, A. A. and West, D. B. : Validation of a radiotelemetry system for continuous blood pressure and heart rate monitoring in dogs. Lab. Animal. Sci. 45, 299 (1995)
- Gelzer, A. R. M. and Ball, H. A. : Validation of a radiotelemetry system for measurement of blood pressure, electrocardiogram and locomotor activity in beagle dogs. Clin. Exp. Hypertens 19, 1135 (1997) https://doi.org/10.3109/10641969709083209
- Radovanovic, D., et al. : Dose-dependent toxicity of diphenhydramine overdose. Hum. Exp. Toxicol. Sep. 19(9), 489 (2000) https://doi.org/10.1191/096032700671040438
- Joshi, A. K., et al. : Case of polymorphic ventricular tachycardia in diphenhydramine poisoning. J. Cardiovasc. Electrophysiol. 15(5), 591 (2004) https://doi.org/10.1046/j.1540-8167.2004.03173.x
- Merk, H. F. : Standard treatment : the role of antihistamines. J. Investig Dermatol. Symp. Proc. 6(2), 153 (2001)
- Yee, G. Y. : Drug induced QT prolongation and torsades de pointes. Heart 89, 1363 (2003) https://doi.org/10.1136/heart.89.11.1363
- Guth, B. B., et al. : Developing a strategy for the nonclinical assessement of proarrhythmic risk of pharmaceuticlas due to prolonged ventricular repolarization. Journal of Pharmacological Toxicological Methods 49, 159 (2004) https://doi.org/10.1016/j.vascn.2004.02.006
- Ajay Joshi, et al. : Preclinical strategies to assess QT liability and torsadogenic potential of new Drugs : the role of experimental models. Journal of Electrocardiology 37, 7 (2004) https://doi.org/10.1016/j.jelectrocard.2004.08.003